Xenon Pharmaceuticals provided an update on its pipeline programs, highlighting significant progress and upcoming milestones for 2025. The company anticipates topline data from its first Phase 3 study ...
In Q1 2023, Xenon had $687.3 million in cash and marketable securities, down from $720.8 million in Q4 2022. They anticipate sufficient funding for operations until 2026. XEN1101, a leading candidate ...
Questions may be submitted (via chat function) during the live webinar or submitted in advance via email to [email protected]. A live webcast of the webinar will be available on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results